🚀 VC round data is live in beta, check it out!
Provexis Valuation Multiples
Discover revenue and EBITDA valuation multiples for Provexis and similar public comparables like Valbiotis, Simris Group, Hofseth BioCare, Mycodern and more.
Provexis Overview
About Provexis
Provexis PLC is engaged in developing, licensing and selling the proprietary, scientific Fruitflow heart-health functional food ingredient for the global functional food sector. The extract is available in two formats, a syrup and a powder, and it can be included in a broad range of food, beverage and dietary supplement formats.
Founded
2004
HQ
Employees
2
Website
Financials (FY)
EV
$32M
Provexis Financials
Provexis reported last fiscal year revenue of $2M and negative EBITDA of ($611K).
In the same fiscal year, Provexis generated $721K in gross profit, ($611K) in EBITDA losses, and had net loss of ($612K).
Provexis P&L
In the most recent fiscal year, Provexis reported revenue of $2M and EBITDA of ($611K).
Provexis expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $2M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $721K | XXX | XXX | XXX |
| Gross Margin | — | XXX | 41% | XXX | XXX | XXX |
| EBITDA | — | XXX | ($611K) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (35%) | XXX | XXX | XXX |
| EBIT Margin | — | XXX | (35%) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($612K) | XXX | XXX | XXX |
| Net Margin | — | XXX | (35%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Provexis Stock Performance
Provexis has current market cap of $33M, and enterprise value of $32M.
Market Cap Evolution
Provexis' stock price is $0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $32M | $33M | 0.0% | XXX | XXX | XXX | $-0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialProvexis Valuation Multiples
Provexis trades at 18.3x EV/Revenue multiple, and (52.3x) EV/EBITDA.
Provexis Financial Valuation Multiples
As of April 19, 2026, Provexis has market cap of $33M and EV of $32M.
Equity research analysts estimate Provexis' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Provexis has a P/E ratio of (53.4x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $33M | XXX | $33M | XXX | XXX | XXX |
| EV (current) | $32M | XXX | $32M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 18.3x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (52.3x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (52.3x) | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 44.4x | XXX | XXX | XXX |
| P/E | — | XXX | (53.4x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (69.4x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Provexis Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Provexis Margins & Growth Rates
Provexis' revenue in the last fiscal year grew by 10%.
Provexis' revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.7M for the same period.
Provexis Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (35%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (8%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 33% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 25% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 76% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Provexis Public Comps
See public comps and valuation multiples for other Nutraceuticals & Cosmeceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Provexis | XXX | XXX | XXX | XXX | XXX | XXX |
| Valbiotis | XXX | XXX | XXX | XXX | XXX | XXX |
| Simris Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Hofseth BioCare | XXX | XXX | XXX | XXX | XXX | XXX |
| Mycodern | XXX | XXX | XXX | XXX | XXX | XXX |
| Aqua Bio Technology | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Provexis M&A Activity
Provexis acquired XXX companies to date.
Last acquisition by Provexis was on XXXXXXXX, XXXXX. Provexis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Provexis
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialProvexis Investment Activity
Provexis invested in XXX companies to date.
Provexis made its latest investment on XXXXXXXX, XXXXX. Provexis invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Provexis
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Provexis
| When was Provexis founded? | Provexis was founded in 2004. |
| Where is Provexis headquartered? | Provexis is headquartered in United Kingdom. |
| How many employees does Provexis have? | As of today, Provexis has over 2 employees. |
| Who is the CEO of Provexis? | Provexis' CEO is Ian Ford. |
| Is Provexis publicly listed? | Yes, Provexis is a public company listed on London Stock Exchange. |
| What is the stock symbol of Provexis? | Provexis trades under PXS ticker. |
| When did Provexis go public? | Provexis went public in 2004. |
| Who are competitors of Provexis? | Provexis main competitors are Valbiotis, Simris Group, Hofseth BioCare, Mycodern. |
| What is the current market cap of Provexis? | Provexis' current market cap is $33M. |
| What is the current revenue of Provexis? | Provexis' last fiscal year revenue is $2M. |
| What is the current EV/Revenue multiple of Provexis? | Current revenue multiple of Provexis is 18.3x. |
| Is Provexis profitable? | No, Provexis is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.